ADM has debuted its GLP-1 support platform designed for anti-obesity medication (AOM) users.
The solution, which is backed by exclusive consumer insights, is designed to provide tailored nutrition to those on their weight loss journey, as well as those who are in the process of discontinuing AOMs.
Through this initiative, ADM has introduced more than 25 market-ready nutraceuticals and functional foods that are suitable for food and supplement concepts.
The products contain a vast variety of functional ingredients, which have been curated to target the specific needs of those taking AOMs.
Each concept is formulated with a specific blend of science-backed prebiotic fibres, probiotics, postbiotics, botanical extracts, as well as keto-friendly starch and flour solutions.
ADM’s nutraceutical GLP-1 support range focuses on five pillars relevant to those taking obesity medications, including:
- Maintaining muscle mass: Through plant-based proteins and wholesome ingredients
- Minimising gastrointestinal discomfort: Prebiotic and probiotic solutions can support the gut health of consumers
- Supporting hydration: ADM’s coconut water powder can make hydration more appealing
- Promoting satiety: Dietary prebiotic fibres can increase satiety perception, allowing users to retain their weight loss
- Managing weight regain: Biotics that target aspects of metabolic health can assist consumers in keeping the weight off post-AOM
Trends and preferences amongst GLP-1 users
According to ADM’s consumer research, 83% of US survey participants on AOMs find food products advertised to support GLP-1 medication users appealing.
Respondents also placed a keen focus on the nutritional value of the food they purchase, with 64% of participants taking this into account when purchasing a food product.
There was also a strong interest in taste (64%) and portion size (60%) amongst the consumer subset.
Further, 74% of participants were open to trying new foods, with more than 80% also aiming to cook more at home.
Many of those taking AOMs also intentionally enhanced their intake of plant-based protein, probiotics & prebiotics and fibre.
ADM’s Senior Vice President, President, Nutrition, and Chief Sales and Marketing Officer, Ian Pinner, commented: “Our tested and ready-to-market concepts tap into our unparalleled pantry and our full-formulation expertise to accelerate food and beverage manufacturers’ speed to market and help them differentiate with elevated format, flavour, texture and functionality,”
“Through our platform, we’re addressing the changing taste preferences that may come with engaging with GLP-1 medications, such as the altered perception of sweetness. We are also delivering highly sought-after nutrient density in smaller servings and providing alternative solutions to support reducing persistent thoughts about food, commonly known as ‘food noise,’ if medication use is reduced.”
